Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections

Overview of attention for article published in European Journal of Clinical Microbiology & Infectious Diseases, November 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

twitter: 52 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 58 X posts from 52 X users, with an upper bound of 171,179 followers.

RT @ABsteward: 🆕️✨️🔥Retrospective cohort study with @pranita_tamma provides further evidence to support treating AmpC beta-lactamase-produ…

28 Nov 2023

Reply Repost Favourite

RT @ABsteward: 🆕️✨️🔥Retrospective cohort study with @pranita_tamma provides further evidence to support treating AmpC beta-lactamase-produ…

28 Nov 2023

Reply Repost Favourite

🌟 More evidence to support the use of #cefepime as a safe treatment strategy for #AmpC 🐛 #BSI 🩸particularly in clinically stable patients without initial renal impairment or increased susceptibility to neurological adverse events 🧐🔝

27 Nov 2023

Reply Repost Favourite

RT @37phoenix: AmpC産生菌菌血症の治療においてセフェピムとカルバペネムで1次アウトカム(院内死亡、腎障害、神経合併症)、2次アウトカム(在院日数、再感染)に差はなかった。神経合併症はカルバ群で多く、セフェピム群で入院期間が短かった。Eur J Clin Mic…

25 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 54 additional X posts.